Sample characteristics in 2019 and 2020 analysis groups
| 2019 | 2020 | |
| Total | 43 | 45 |
| Median age (years) (range) | 65.7 (39–84) | 65.0 (20–90) |
| Sex (%)–median age (years) (range) | M: 28 (65.1)–67.7 (39–84) F: 15 (34.9)–62.1 (45–74) | M: 28 (62.2)–65.5 (42–88) F: 17 (37.8)–64.1 (20–90) |
| Adequate (%) versus inadequate samples (%) | 42 (97.7) vs 1 (2.3) | 41 (91.1) vs 4 (8.9) |
| Platform, n (%) | NGS, 32 (76.2) Idylla, 4 (9.5) NGS+Tape Station, 3 (7.1) Tape Station, 2 (4.8%) RT-PCR, 1 (2.4) | Idylla, 38 (92.7) NGS, 3 (7.3) |
| Median TAT (days) (range) | 7.9 (3–22) | 5.3 (1–12) |
| Sample type, n (%) - subtype, n (%) | Histological, 33 (78.6) Resection, 24 (72.7) Biopsy, 9 (27.3) Cytological, 8 (19.0) Cell block, 6 (75.0) Smear 2 (25.0) Extracted DNA, 1 (2.4) | Histological, 32 (78.0) Resection, 24 (75.0) Biopsy, 8 (25.0) Cytological, 8 (19.5) Cell block, 8 (100.0) Extracted DNA, 1 (2.5) |
| Diagnosis, n (%) | Lung ADC, 20 (47.6) Colon ADC, 18 (42.8) GIST, 2 (4.8) Melanoma, 1 (2.4) Cystic teratoma, 1 (2.4) | Lung ADC, 18 (43.9) Colon ADC, 15 (36.6) Melanoma, 5 (12.2) GIST, 2 (4.9) Thyroid anaplastic carcinoma, 1 (2.4) |
ADC, adenocarcinoma; F, female; GIST: gastrointestinal stromal tumour; M: male; n: number; NGS: next-generation sequencing; RT-PCR, real-time PCR; TAT, turnaround time.